{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT00033384: Phase 2 Interventional Completed Breast Cancer
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
CI 1040 is an inhibitor of the mitogen-activated protein (MAP) kinase signal transduction pathway and has been shown to specifically inhibit MAP kinase kinase (MEK). CI 1040 was being developed by Parke-Davis (formerly a division of WarnerLambert, Now Pfizer) as an anticancer agent. It was the initial MEK inhibitor to undergo clinical evaluation based on promising preclinical activity. However, its development has been discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Metesculetol (permethol) is a vitamin P derivative. It increases capillary resistance and reduces membrane permeability. Permethol is for damaged gums and helps to stop gum bleeding, relieves inflammation and nourishes the gum tissues. It is used as a component of products for oral cavity care.
Class (Stereo):
CHEMICAL (RACEMIC)
Tetriprofen is a hydratropic acid derivative patented by Swiss chemical company CIBA Ltd as an antinociceptive and anti-inflammatory agent.
Class (Stereo):
CHEMICAL (RACEMIC)
Texacromil is a benzopyran derivative patented by C. M. Industries S. A. as passive cutaneous anaphylaxis inhibitor
Class (Stereo):
CHEMICAL (ABSOLUTE)
Fomidacillin (also known as BRL 36650) is a type of penicillin with antibacterial activity. Studies on volunteers have shown that the drug possessed the bactericidal activity and could be a candidate for the treatment of gram-negative bacillary infections. However, information about the further development of this drug is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Fosmidomycin (3-(formylhydroxyamino)-propylphosphonic acid mono-sodium salt, 3-(N-formyl-N-hydroxyamino)-propylphosphonic acid mono-sodium salt, FR-31564) is a potent inhibitor of P. falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (PfDXR), developed by Albert Schweitzer Hospital for P. falciparum malaria treatment. Fosmidomycin was originally isolated as natural antibiotic from Streptomyces lavendulae. Fosmidomycin is active against a broad range of enterobacteria, but not against Gram-positive organisms or anaerobes. Fosmidomycin was developed as far as an early phase II study for the treatment of urinary tract infections by Fujisawa Pharmaceutical Company (Osaka, Japan) in the early eighties, but these trials have been discontinued. In recent clinical studies, it was shown that fosmidomycin is effective in curing uncomplicated Plasmodium falciparum malaria in humans. The treatment was well tolerated and resulted in a fast parasite and fever clearance. However, the high rate of recrudescence precludes the use of fosmidomycin as a monotherapy. In drug combination studies, the synergy of fosmidomycin with clindamycin was observed. Clinical studies with a fosmidomycin-clindamycin combination are currently ongoing.
Class (Stereo):
CHEMICAL (MIXED)
Fosmenic acid was used for the treatment of atherosclerosis. Information about the current use of this drug is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Tigloidine is a tropane alkaloid and a naturally occurring analog of atropine, found in small quantities in Duboisia myoporoides. Tigloidine has been found to be beneficial in the treatment of Parkinsonism, Huntington’s Chorea and spastic paraplegia. Tigloidine may provide relief in parkinsonian patients by increasing the gamma-efferent activity and reducing alpha motoneurone activity. In preclinical models, Tigloidine failed to reverse sedation and ptosis in rats induced by reserpine and tetrabenazine. In mice, amphetamine response was not significantly affected by Tigloidine or atropine. However, in the cat and dog, it was markedly facilitated by Tigloidine but not by atropine.
Status:
Investigational
Source:
INN:flindokalner [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Flindokalner (BMS 204352; MaxiPost™) is a neuroprotective agent with potential in the treatment of stroke developed by Bristol-Myers Squibb. Flindokalner is a potent and effective opener of two important subtypes of neuronal potassium channels, the calcium-activated, big-conductance potassium channels (K(Ca) channels) and voltage-dependent, non-inactivating potassium channels known as KCNQ channels. Flindokalner significantly reduced cortical infarct volume in a animal models of stroke. Flindokalner failed to show superior efficacy in acute stroke patients compared to placebo in a Phase III study.
Status:
Investigational
Class (Stereo):
CHEMICAL (MIXED)
Tiapirinol is a thiazine derivative patented by Tanabe Seiyaku Co., Ltd. as a low toxic compound useful to prevent hypohepatia. In acute toxicity tests on mice, the toxicity of Tiapirinol is lower than that of pyridoxal phosphate and other vitamin B6 derivative. Tiapirinol showed vitamin B6 activity approximately equivalent to that of pyridoxal phosphate or pyridoxine for the growth of vitamin B6 deficient rats and also for the convulsions caused by antivitamin B6 agents.
